T1 Biomarker 1069 1086 oral capecitabine
T2 Organism 2297 2305 patients
T3 Biomarker 444 472 gemcitabine and capecitabine
T4 Biomarker 2313 2330 gemcitabine group
T5 Biomarker 2313 2324 gemcitabine
T6 Condition 272 278 tumour
T7 Organism 1932 1940 patients
T8 Biomarker 2064 2075 gemcitabine
T9 Biomarker 1727 1738 gemcitabine
T10 Biomarker 2064 2081 gemcitabine group
T11 Organism 2188 2196 patients
T12 Gene_or_gene_product 2264 2267 3–4
T13 Biomarker 1948 1959 gemcitabine
T14 Biomarker 49 60 gemcitabine
T16 Disease 1412 1420 Toxicity
T17 Condition 2461 2493 pancreatic ductal adenocarcinoma
T18 Organism 1441 1449 patients
T19 Organism 883 891 patients
T20 Biomarker 487 498 gemcitabine
T21 Biomarker 332 343 gemcitabine
T22 Biomarker 2389 2401 capecitabine
T24 Organism 177 185 patients
T25 Biomarker 1704 1715 gemcitabine
T26 Biomarker 2204 2233 gemcitabine plus capecitabine
T27 Disease 123 131 toxicity
T28 Condition 802 823 ductal adenocarcinoma
T29 Biomarker 2204 2215 gemcitabine
T30 Biomarker 2221 2233 capecitabine
T31 Condition 200 217 pancreatic cancer
T32 Biomarker 293 321 gemcitabine and capecitabine
T33 Condition 365 393 metastatic pancreatic cancer
T34 Gene_or_gene_product 2141 2144 3–4
T35 Intervention 831 839 pancreas
T37 Organism 712 720 patients
T38 Biomarker 2373 2384 gemcitabine
T43 Gene 161 173 folinic acid
T44 Biomarker 1727 1756 gemcitabine plus capecitabine
T45 Biomarker 293 304 gemcitabine
T47 Condition 524 541 pancreatic cancer
T49 Biomarker 444 455 gemcitabine
T50 Biomarker 1948 1977 gemcitabine plus capecitabine
T51 Gene 146 160 5-fluorouracil
T52 Organism 1596 1604 patients
T53 Protein 2033 2037 25·5
